CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Clinical trial NCT04495153 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04495153
- Sponsor
- Candel Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-13
- Primary completion
- 2024-12-31
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.